{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:50Z","timestamp":1784804810306,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4261,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Albumin dialysis has been shown to improve the outcome in patients with cholestatic liver failure caused by chronic liver disease. This study reports 7 liver transplant recipients who were treated with albumin dialysis for intractable pruritus of different origin (ductopenic graft rejection, non-anastomotic strictures, and recurrence of hepatitis C). Treatment with histamine (H1) blockers, opioid antagonists, and cholestyramine had not been effective. The Molecular Adsorbent Recirculating System (MARS; Teraklin, Rostock, Germany) was used for albumin dialysis. All patients presented with numerous scratch marks, 6 of whom had a pronounced icterus. Six patients (86%) responded to 3 consecutive treatments with significant reduction of pruritus. The mean pruritus score, which was quantified by a visual analog scale (VAS), decreased from 9.7 \u00b1 0.5 to 3.7 \u00b1 0.8 (SD). The mean duration of 1 treatment was 15.6 hours. The procedure was well tolerated by all patients. The mean total serum bilirubin in patients who responded to therapy declined from 19.11 \u00b1 16.96 mg\/dL (SD) before MARS therapy to 9.24 \u00b1 3.52 mg\/dL after treatment. The mean serum concentration of 3\u03b1-hydroxy bile acids decreased from 192.67 \u00b1 58.12 \u03bcmol\/L (SD) to 42.33 \u00b1 31.58 \u03bcmol\/L (SD). Follow-up in 3 cases showed sustained improvement of pruritus lasting for more than 3 months. In 3 patients, however, pruritus relapsed. One patient, who showed severe pruritus, without relevant elevation of serum bile acids before treatment, did not respond to albumin dialysis. Our data indicate that MARS is an effective therapeutic option for patients with intractable cholestatic pruritus. (Liver Transpl 2004;10:107-114.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20001","type":"journal-article","created":{"date-parts":[[2004,1,7]],"date-time":"2004-01-07T09:01:56Z","timestamp":1073466116000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":75,"title":["Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis"],"prefix":"10.1097","volume":"10","author":[{"given":"Romuald","family":"Bellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo W.","family":"Graziadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Feistritzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schwaighofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Stellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Wiedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-16-20250326","first-page":"S28","article-title":"Liver transplantation for cholestatic liver disease: screening and assessment of risk factors.","volume":"4","author":"Crippin","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R2-16-20250326","doi-asserted-by":"crossref","first-page":"10051013","DOI":"10.1053\/he.2000.5984","article-title":"Management of primary biliary cirrhosis.","volume":"31","author":"Heathcote","year":"2000","journal-title":"Hepatology"},{"key":"R3-16-20250326","doi-asserted-by":"crossref","first-page":"644645","DOI":"10.1136\/gut.38.5.644","article-title":"Why do cholestatic patients itch?","volume":"38","author":"Jones","year":"1996","journal-title":"Gut"},{"issue":"suppl 2","key":"R4-16-20250326","first-page":"1419","article-title":"Cholestatic liver disease: pathophysiology and therapeutic option.","volume":"22","author":"Hofmann","year":"2002","journal-title":"Liver"},{"key":"R5-16-20250326","doi-asserted-by":"crossref","first-page":"451456","DOI":"10.1007\/s11938-999-0048-8","article-title":"Pruritus.","volume":"2","author":"Franco","year":"1999","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R6-16-20250326","doi-asserted-by":"crossref","first-page":"938948","DOI":"10.1046\/j.1440-1746.2002.02717.x","article-title":"Extrahepatic manifestations of cholestasis.","volume":"17","author":"Glasova","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-16-20250326","first-page":"773776","article-title":"Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids.","volume":"6","author":"Di Padova","year":"1984","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R8-16-20250326","doi-asserted-by":"crossref","first-page":"436439","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"key":"R9-16-20250326","first-page":"574576","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"key":"R10-16-20250326","doi-asserted-by":"crossref","first-page":"161167","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusion in patients with the pruritus of cholestasis: a double blind randomized controlled trial.","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"key":"R11-16-20250326","doi-asserted-by":"crossref","first-page":"865870","DOI":"10.1097\/00042737-199810000-00010","article-title":"Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.","volume":"10","author":"Muller","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R12-16-20250326","doi-asserted-by":"crossref","first-page":"254260","DOI":"10.1111\/j.1600-0625.1999.tb00379.x","article-title":"The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletionan experimental study.","volume":"8","author":"Weisshaar","year":"1999","journal-title":"Exp Dermatol"},{"key":"R13-16-20250326","doi-asserted-by":"crossref","first-page":"135140","DOI":"10.1159\/000198704","article-title":"Removal of bile acids from the blood by hemodialysis with a polyacrylonitrile membrane: treatment of pruritus of cholestatic disease.","volume":"23","author":"Hoek","year":"1982","journal-title":"Digestion"},{"key":"R14-16-20250326","first-page":"233236","article-title":"Therapeutic plasmapheresis for cholestatic liver diseases: study of 9 cases.","volume":"337","author":"Omokawa","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"R15-16-20250326","first-page":"239244","article-title":"Treatment of intractable pruritus in patients with cholestatic jaundice by plasma exchange and plasma perfusion.","volume":"21","author":"Geerdink","year":"1978","journal-title":"Neth J Med"},{"issue":"suppl 17","key":"R16-16-20250326","first-page":"S75S82","article-title":"Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.","volume":"12","author":"Mitzner","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R18-16-20250326","doi-asserted-by":"crossref","first-page":"676679","DOI":"10.1016\/S0025-6196(12)65347-6","article-title":"Classification and terminology of hepatic allograft rejection: whither bound?","volume":"64","author":"Ludwig","year":"1989","journal-title":"Mayo Clin Proc"},{"issue":"suppl 2","key":"R19-16-20250326","first-page":"7275","article-title":"Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC).","volume":"22","author":"Sturm","year":"2002","journal-title":"Liver"},{"key":"R20-16-20250326","doi-asserted-by":"crossref","first-page":"413414","DOI":"10.1016\/S0168-8278(02)00177-0","article-title":"Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS).","volume":"37","author":"Huster","year":"2002","journal-title":"J Hepatol"},{"key":"R21-16-20250326","doi-asserted-by":"crossref","first-page":"609611","DOI":"10.1002\/bms.1200141106","article-title":"Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling.","volume":"14","author":"Stellaard","year":"1987","journal-title":"Biomed Environ Mass Spectrom"},{"key":"R22-16-20250326","doi-asserted-by":"crossref","first-page":"463475","DOI":"10.1023\/A:1021986624600","article-title":"Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARSa review of clinical, biochemical and electrophysiological data.","volume":"17","author":"Mitzner","year":"2002","journal-title":"Metab Brain Dis"},{"key":"R23-16-20250326","first-page":"512","article-title":"Sali biliari e rilascio spontaneo di PGI2, TxA2 e fVIII dalle cellule endoteliali umane in coltura.","volume":"5","author":"Calcamuggi","year":"1990","journal-title":"Ann Ital Med Int"},{"key":"R24-16-20250326","doi-asserted-by":"crossref","first-page":"137145","DOI":"10.1172\/JCI4765","article-title":"Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.","volume":"103","author":"Faubion","year":"1999","journal-title":"J Clin Invest"},{"key":"R25-16-20250326","doi-asserted-by":"crossref","first-page":"693701","DOI":"10.1016\/S0016-5085(98)70149-0","article-title":"Cholestasis confers resistance to the rat liver mitochondrial permeability transition.","volume":"115","author":"Lieser","year":"1998","journal-title":"Gastroenterology"},{"key":"R26-16-20250326","doi-asserted-by":"crossref","first-page":"424429","DOI":"10.1016\/S0168-8278(98)80060-3","article-title":"Polyethylene glycol-modified bilirubin oxidase improves hepatic energy charge and urinary prostaglandin levels in rats with obstructive jaundice.","volume":"29","author":"Kamisako","year":"1998","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"R27-16-20250326","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0168-8278(02)80559-1","article-title":"Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis. abstract.","volume":"36","author":"Pares","year":"2002","journal-title":"J Hepatol"},{"issue":"suppl","key":"R28-16-20250326","first-page":"1314","article-title":"Successful clinical application of extracorporeal albumin dialysis in a patient with recurrent intrahepatic cholestasis (BRIC).","volume":"39","author":"Huster","year":"2001","journal-title":"Z Gastroenterol"},{"key":"R29-16-20250326","doi-asserted-by":"crossref","first-page":"437443","DOI":"10.1053\/jlts.2003.50055","article-title":"Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus.","volume":"9","author":"Doria","year":"2003","journal-title":"Liver Transpl"},{"key":"R30-16-20250326","doi-asserted-by":"crossref","first-page":"10591060","DOI":"10.1111\/j.1572-0241.2002.05629.x","article-title":"MARS dialysis in the state of chronic rejection in a liver transplant recipient.","volume":"97","author":"Schachschal","year":"2002","journal-title":"Am J Gastroenterol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20001","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200401000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:28:17Z","timestamp":1743233297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200401000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20001","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}